A two year sibutramine trial of obesity reduction and maintenance (STORM);Sibutramin - Antidepressivt läkemedel prövat mot fetma

Lakartidningen

Volumn 98, Issue 15, 2001, Pages 1802-1803

  Rössner, Stephan ^a,b  

^a Huddinge Universitetssjukhus ^*  (Sweden)

^b Huddinge Universitetssjukhus   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANOREXIGENIC AGENT; ANTIDEPRESSANT AGENT; CYCLOBUTANE DERIVATIVE; SEROTONIN UPTAKE INHIBITOR; SIBUTRAMINE;

ARTICLE; BODY MASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET THERAPY; HUMAN; LOW CALORY DIET; OBESITY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; APPETITE DEPRESSANTS; BODY MASS INDEX; CYCLOBUTANES; DIET, REDUCING; HUMANS; OBESITY; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 0035843678     PISSN: 00237205     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (7)

1. Bray GA. Contemporary diagnosis and management of obesity. Pennsylvania: Handbooks in Health Care Co, 1998.
2. Rössner S, Sjöström L, Noack R, Meinders E, Nosedal G. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. Obes Res 2000; 8: 49-61.
3. Bray GA, Blackburn GL, Ferguson JM, Greenway FL, Jain AK Mendel CM et al. Sibutramine produces dose-related weight loss. Obes Res 1999; 7: 189-98.
4. Apfelbaum M, Vague P, Ziegler O, Hanotin C, Thomas F, Lentenegger E. Long-term maintenance of weight loss after a very-low-calorie diet: a randomised blinded trial of the efficacy and tolerability of sibutramine. Am J Med 1999; 106: 179-84.
5. James WPT, Astrup A, Finer N, Hilsted J, Kopelman P, Rössner S et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM study group. Sibutramine trial of obesity reduction and maintenance. Lancet 2000; 356: 2119-25.
6. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans affairs high-density lipoprotein cholesterol intervention trial study group. N Engl J Med 1999; 341: 410-8.
7. Rooth P, Hyll M, Rössner S. High prevalence of anxiety and depressive symptoms in obese patients. International Journal of Obesity 1999; 23 suppl 5: 159.